What Is Survodutide? The Dual GLP-1 and Glucagon Agonist Being Studied for Obesity

Survodutide is one of the most advanced next-generation peptide drugs being studied for obesity and metabolic disease.

Unlike traditional GLP-1 receptor agonists, survodutide targets two hormone pathways at once:

• the GLP-1 receptor
• the glucagon receptor

That dual mechanism is designed to combine reduced food intake with increased metabolic activity.

And unlike many experimental compounds that remain in early development, survodutide now has published Phase 3 human data.

What Is Survodutide?

Survodutide, also known as BI 456906, is an investigational once-weekly peptide developed by Boehringer Ingelheim and Zealand Pharma.

It acts as a dual glucagon receptor and GLP-1 receptor agonist.

This means that a single molecule activates both signalling pathways.

GLP-1 activation is already well established in modern metabolic medicine.

Glucagon activation is more unusual.

Researchers are investigating whether combining the two signals can produce metabolic effects that go beyond GLP-1 alone.

What Does GLP-1 Do?

GLP-1 is a naturally occurring gut hormone released after eating.

It influences:

• appetite
• satiety
• insulin secretion
• blood glucose regulation
• gastric emptying

Activating the GLP-1 receptor can therefore reduce food intake while improving several aspects of metabolic regulation.

What Does Glucagon Do?

Glucagon is another naturally occurring peptide hormone.

It is best known for increasing blood glucose when levels fall too low.

But glucagon also has broader metabolic effects.

Researchers are particularly interested in its ability to influence:

• energy expenditure
• fat metabolism
• liver metabolism
• thermogenesis

This creates an interesting theoretical combination.

GLP-1 may help reduce energy intake, while glucagon signalling may increase energy use.

Why Combine GLP-1 and Glucagon?

Modern obesity research increasingly focuses on multi-receptor agonists.

Instead of relying on one biological signal, researchers are attempting to activate complementary hormone pathways simultaneously.

With survodutide, the basic idea is:

GLP-1 → reduce appetite and food intake

plus

glucagon → potentially increase energy expenditure and alter metabolism

The balance between those two receptor activities is critical.

Too much glucagon activity could potentially raise blood glucose, while too little might reduce the metabolic advantage of the dual approach.

Designing the peptide therefore involves finding an appropriate balance between the two signals.

Has Survodutide Reached Phase 3?

Yes.

Survodutide has now produced published Phase 3 results in both:

• adults with obesity without diabetes
• adults with obesity and type 2 diabetes

That puts it considerably further along the research pathway than many emerging metabolic peptides.

What Did the Phase 3 Obesity Trial Show?

The SYNCHRONIZE-1 Phase 3 trial enrolled 725 adults with obesity or overweight plus an obesity-related complication who did not have diabetes.

Participants received once-weekly survodutide at doses adjusted up to:

• 3.6 mg
• 6.0 mg
• or placebo

Treatment continued for 76 weeks alongside lifestyle counselling.

At week 76, average body-weight changes were approximately:

• –12.2% with 3.6 mg survodutide
• –13.0% with 6.0 mg
• –5.4% with placebo

More than 70% of participants receiving survodutide achieved at least 5% weight reduction. (New England Journal of Medicine⁠)

How Significant Are Those Results?

They show that survodutide clearly produced greater average weight reduction than placebo.

However, headline percentages need context.

The placebo group also lost a meaningful amount of weight because participants received lifestyle support.

The trial also used a treatment-regimen analysis that included participants regardless of whether they discontinued treatment or used prohibited obesity therapies.

That makes the reported result useful for understanding effectiveness under more realistic conditions.

What About People With Type 2 Diabetes?

A second Phase 3 trial, SYNCHRONIZE-2, examined survodutide in adults with both obesity and type 2 diabetes.

The trial enrolled 752 participants.

At week 76, average weight changes were approximately:

• –8.2% with 3.6 mg
• –9.8% with 6.0 mg
• –3.9% with placebo

Participants receiving survodutide also experienced larger reductions in glycated haemoglobin, or HbA1c, than those receiving placebo. (New England Journal of Medicine⁠)

Why Was Weight Loss Lower in People With Diabetes?

This pattern is common in obesity trials.

People with type 2 diabetes often experience somewhat smaller average weight reductions than people without diabetes when using metabolic therapies.

Several factors may contribute, including:

• differences in insulin resistance
• medications
• metabolic adaptation
• duration of diabetes
• other underlying metabolic factors

The important point is that survodutide still produced significantly greater weight reduction than placebo in the diabetic population.

What Were the Most Common Side Effects?

Gastrointestinal effects were the most commonly reported adverse events.

In SYNCHRONIZE-1, gastrointestinal events occurred in approximately:

• 80.9% of participants receiving 3.6 mg
• 89.7% receiving 6.0 mg
• 47.9% receiving placebo

These events were generally described as mild to moderate. (New England Journal of Medicine⁠)

In SYNCHRONIZE-2, gastrointestinal events were also the most common adverse events and were generally mild to moderate and transient. (New England Journal of Medicine⁠)

Does Survodutide Increase Metabolism?

The glucagon component is one reason researchers believe survodutide may influence energy expenditure and fat metabolism.

However, it is better to avoid simplifying the mechanism into claims that it simply “boosts metabolism”.

Human metabolism is complex.

The observed clinical effects reflect multiple biological processes occurring simultaneously.

How Is Survodutide Different From Semaglutide?

Semaglutide primarily targets the GLP-1 receptor.

Survodutide activates both:

• GLP-1
• glucagon

That makes survodutide a dual agonist rather than a single-receptor agonist.

The additional glucagon component is intended to produce complementary metabolic effects.

How Is Survodutide Different From Tirzepatide?

Tirzepatide targets:

• GIP
• GLP-1

Survodutide targets:

• glucagon
• GLP-1

Both are dual agonists, but the second receptor is completely different.

This means the two drugs represent different strategies for extending beyond GLP-1 alone.

How Is Survodutide Different From Retatrutide?

Retatrutide targets three receptors:

• GIP
• GLP-1
• glucagon

Survodutide targets two:

• GLP-1
• glucagon

Retatrutide therefore includes GIP activity in addition to the pathways targeted by survodutide.

That does not automatically mean three receptors are better than two.

The balance and strength of receptor activation can matter as much as the number of receptors targeted.

Why Is Glucagon Becoming So Important?

For decades, glucagon was mostly discussed in relation to blood glucose.

Obesity researchers are now exploring its wider metabolic effects.

Glucagon signalling can influence:

• liver metabolism
• lipid mobilisation
• energy expenditure
• thermogenesis

This makes it an attractive pathway for combination therapies.

The challenge is achieving metabolic benefits without producing excessive increases in glucose.

Is Survodutide Being Studied for Liver Disease?

Yes.

One of the most interesting aspects of glucagon/GLP-1 dual agonism is its potential effect on liver metabolism.

Survodutide has also been studied in people with metabolic dysfunction-associated steatohepatitis, commonly abbreviated to MASH.

That makes the compound interesting beyond obesity alone.

Its effects on liver fat and metabolic pathways may ultimately become an important part of its clinical profile.

Is Survodutide Approved?

No.

Survodutide remains an investigational medicine.

Despite having Phase 3 data, it has not yet become an established approved therapy.

Further regulatory review and additional clinical evidence are still required.

What Research Is Still Ongoing?

The SYNCHRONIZE programme continues to expand.

A new Phase 3b study is examining different ways of starting survodutide, including people switching from semaglutide or tirzepatide.

Another ongoing Phase 3 trial is investigating survodutide specifically for blood-glucose control in people with type 2 diabetes. (patient.boehringer-ingelheim.com⁠)

This suggests researchers are already moving beyond the basic question of whether the drug works and toward questions about how it might eventually fit into clinical practice.

Could Survodutide Be Used After Semaglutide or Tirzepatide?

Researchers are actively investigating that possibility.

The SYNCHRONIZE-START programme includes people who have previously used semaglutide or tirzepatide and evaluates different strategies for switching to survodutide. (patient.boehringer-ingelheim.com⁠)

That is particularly interesting because future metabolic treatment may involve moving between different receptor combinations rather than simply increasing the dose of one therapy indefinitely.

Is Survodutide a Peptide?

Yes.

Survodutide is a peptide-based dual receptor agonist.

Its structure has been engineered to activate both the GLP-1 and glucagon receptors while allowing once-weekly administration.

Why Is Survodutide Important?

Survodutide represents the broader evolution of metabolic peptide research.

The progression has roughly moved from:

single receptor

GLP-1

to

dual receptor

GLP-1 + GIP

or

GLP-1 + glucagon

and now toward

triple receptor

GLP-1 + GIP + glucagon

Researchers are increasingly investigating which combination provides the best balance between:

• appetite suppression
• metabolic activity
• glucose regulation
• body composition
• tolerability

Survodutide is one of the most advanced examples of the GLP-1/glucagon approach.

The Bottom Line

Survodutide is an investigational once-weekly dual GLP-1 and glucagon receptor agonist.

Published Phase 3 research now demonstrates significantly greater weight reduction than placebo in adults with obesity both with and without type 2 diabetes. (New England Journal of Medicine⁠)

In adults without diabetes, average weight reduction reached approximately 13% at 76 weeks with the 6 mg regimen.

In adults with obesity and type 2 diabetes, average reduction reached approximately 9.8% with the same dose.

The results confirm that GLP-1/glucagon dual agonism is no longer simply an experimental concept.

It is now a mechanism supported by late-stage human clinical evidence.

Survodutide remains investigational, however, and its eventual place alongside therapies such as semaglutide, tirzepatide and retatrutide will depend on regulatory decisions, longer-term safety data and direct comparisons.

For researchers following the evolution of metabolic peptides, survodutide is one of the most important dual agonists to watch.

This article is for research and educational purposes only. Survodutide remains investigational and is not presented as an approved or established treatment.